Tag Archives: Treatment

The Buenos Aires patient: Argentinian woman controls HIV for at least 12 years after stopping treatment

An Argentinian woman, now in her 50s, has controlled HIV below the limits of detection since stopping HIV treatment due to side-effects in 2007, researchers from Buenos Aires and the US National Institutes of Health report. The woman no longer has antibodies to HIV and researchers found only a small number of cells containing HIV… Read More »

More weight gain in people starting HIV treatment with newer integrase inhibitors or darunavir

A US study has concluded that weight gain is greater by around 2 to 4kg in HIV-positive people taking bictegravir or dolutegravir as part of their first antiretroviral therapy (ART), compared to their counterparts using other drug regimens. A similar effect was reported in those using the protease inhibitor darunavir. The study led by Dr… Read More »

US HIV infections could drop by 94% before 2030, if treatment is prioritised

Modelling estimates suggest that new HIV infections in the US could be reduced by as much as 94% before 2030, if the current HIV prevention budget is spent more efficiently. Priorities would be linking those diagnosed with HIV to care, ensuring that they receive treatment and getting them to the point of viral suppression. Less… Read More »

Vitamin C Treatment for COVID-19 Being Silenced

In the video above, Dr. Andrew Saul, editor-in-chief of the Orthomolecular Medicine News Service, presents valuable information on the importance of vitamin C for disease treatment, including COVID-19 — information that’s being widely silenced via organized censorship.1 His Tokyo presentation, “Orthomolecular Medicine and Coronavirus Disease: Historical Basis for Nutritional Treatment,” highlights the fact that when… Read More »

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma

PRINCETON, N.J.–(BUSINESS WIRE) October 2, 2020 — Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with unresectable malignant pleural… Read More »